Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues, net $ 134,899 $ 3,620
Operating expenses:    
Cost of implants and other costs 0 1,667
Research and development 161,919 213,834
Selling, general and administrative 886,083 750,098
Depreciation and amortization 24,843 6,713
Total operating expenses 1,072,845 972,312
Loss from operations (937,946) (968,692)
Other income (expenses):    
Interest expense - related parties (160,128) (186,828)
Interest expense, net (87,483) (181,820)
Loss on settlement of debt (132,514) 0
Grant income 413,979 112,963
Change in fair value of upfront purchase price liability (4,500) 0
Change in fair value of royalty liability (2,611) 0
Other miscellaneous expense 59,439 (13,086)
Total other income (expense) 86,182 (268,771)
Loss before provision for income taxes (851,764) (1,237,463)
Income Tax 0 0
Net loss (851,764) (1,237,463)
Non-controlling interest 10,357 687
Net loss attributable to BioCorRx Inc $ (841,407) $ (1,236,776)
Net loss per common share, basic and diluted $ (0.06) $ (0.14)
Weighted average number of common shares outstanding, basic and diluted 15,094,736 8,757,859